Abstract
Obesity, 21(12): E669--78, 2013

Immunohistochemical determination of changes in hypothalamic c--fos or p--ERK1/2 expression in response to PP and/or PYY3--36 injection
After 24 h fasting, WT, Y2−/−, Y4−/−, or Y2Y4−/− mice were i.p. injected with either PP (200 µg/kg BW), PYY3--36 (300 µg/kg BW), the combination of PP and PYY3--36 at these same doses, or saline vehicle (200 µl) between 10:00 and 12:00 h. Immediately thereafter, mice were given access to food. At 30 min after i.p. injection and provision of food, the mice were anaesthetized and the brains were perfused with saline and then 4% paraformaldehyde (PFA). Brains were postfixed in 4% PFA, then placed in 30% sucrose overnight and cut at 30 µm, and immunohistochemistry was performed as described in Supporting Information Experimental Procedures. After cover slipping, 12 sections from each mouse were visualized and counted for c--fos or p--ERK1/2 immunoreactivity within the brain nuclei of interest, using a Zeiss Axioplan light microscope. Double--blind counting of the c--fos--positive and p--ERK1/2 positive neurons was conducted.
Determination of co--localization of c--fos and NPY neurons in NPYGFP mice
Transgenic mice expressing the green fluorescence gene (GFP) under the endogenous mouse NPY promoter (B6.FVB--Tg(Npy--hrGFP)1Lowl/J) were obtained from Jackson Laboratory ([22] ). After 24 h fasting, NPYGFP mice were i.p. injected with PYY3--36 (300 µg/kg BW) between 10:00 and 12:00 h following refeeding. Thirty minutes after injection, these mice were perfused with 4% PFA as described earlier. Brain sections were incubated with the primary antibody, rabbit--anti--mouse c--fos (1:2,000 dilution, Santa Cruz) following the protocol described in Supporting Information Experimental Procedures. Sections were visualized for c--fos immunoreactivity in NPYGFP transgenic mice using a Zeiss Axiophot microscope (Carl Zeiss).
Statistical analyses
Two--way ANOVA were used to determine the significance of interactions and treatments (GraphPad Prism 5, Version 5.0a, GraphPad Software, Inc.). When there was a significant overall effect or interaction effect, Bonferroni post--hoc tests were performed to identify differences among means. F values and degrees of freedom between groups and within groups were reported. P < 0.05 was considered significant. Results Additive effect of peripherally administrated PYY3--36 and PP on food intake I.p. injection of PYY3--36 or PP alone into WT mice significantly reduced fasting--induced food intake, as compared to saline--injected controls ( Figure 1A ). Interestingly, there was no difference in food intake between PYY3--36--injected and PP--injected mice, indicating an equal efficacy of PYY3--36 and PP in inhibiting food intake in fasted WT mice. Importantly, simultaneous injection with both PYY3--36 and PP led to a further reduction in food intake, when compared to the individual administration alone, to a level suggestive of an additive effect of PYY3--36 and PP on inhibiting food intake.
Whereas i.p. injection of PYY3--36 alone into WT mice induced a marked reduction in food intake, no such effect was observed in Y2−/− mice injected with PYY3--36 alone ( Figure 1B) , consistent with Y2 receptor signaling being required for PYY3--36 induced inhibition in food intake. On the other hand, PP injection alone into Y2−/− mice resulted in a similar reduction in food intake to that seen in WT mice, while the combination of PYY3--36 and PP administration into Y2−/− mice led to a food intake comparable to that of PP injection alone ( Figure 1B) , suggesting little involvement of Y2 receptors in the PP--induced anorexigenic action. On the other hand, PYY3--36 administration on its own was able to decrease food intake in Y4−/− mice to a level comparable to its effect in WT mice ( Figure 1C compared to Figure 1A) , indicating a lack of involvement of Y4 receptors in this process, whereas in the absence of Y4 receptors PP lost its capacity to reduce food intake ( Figure 1C ). Y4−/− mice injected with both PYY3--36 and PP showed a decreased food intake similar to that seen in PYY3--36 alone. Collectively, these data not only confirm that PYY3--36 and PP inhibit food intake via Y2 and Y4 receptor signaling, respectively, but also indicate that the anorexigenic actions of PYY3--36 and PP are likely mediated via distinct and additive mechanisms.
PYY3--36 and PP activate differential sets of neurons in the hypothalamic Arc
In order to understand the underlying mechanisms via which combined PYY3--36 and PP treatment elicits anorexigenic actions, we tracked and compared changes in expression of c--fos, an early neuronal activation marker, in key hypothalamic nuclei that are critical in the regulation of energy homeostasis, in response to i.p. PYY3--36 and/or PP injection. Based on previous experiments ( [24] ), c--fos expression at 30 min post--injection was chosen to represent initial activation.
FIGURE 1
Effect of combined injection of PYY3-36 and PP on food intake and distinct pattern of c-fos immunoreactivity in the Arc of WT mice. Fasting-induced food intake was measured at 24 h after injection in WT (A), Y2 2/2 (B) or Y4 2/2 (C) mice. Data are means 6 SEM of 5-6 mice per group. Interaction F (6, 54) 5 6.173; Genotype F (2, 54) 5 4.815; Treatment F (2, 54) 5 25.70. * P < 0.05 and ** P < 0.01 versus saline-injected genotype-matched controls or the comparisons indicated by horizontal bars above. Photomicrograph of coronal sections from WT mice showing c-fos immunoreactivity at 30 min after i.p. injection of either saline (D), PYY3-36 (E), PP (F) or in combination (G). Schematic diagram (H) of dorsal aspect of the Arc of the hypothalamus (ArcD) and lateral aspect of the Arc of the hypothalamus (ArcL) (boxed area, adapted from permission from Ref. 23 ). Scale bar 5 60 mm. Images are representative of five mice per group. Arc: arcuate nucleus, 3V: the third cerebral ventricle.
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Obesity | VOLUME 21 | NUMBER 12 | DECEMBER 2013 www.obesityjournal.org As shown in Table 1 and in Figure 1D and E, when WT mice were injected with PYY3--36 alone, significant increases in the number of c--fos immunoreactive neurons were detected in several hypothalamic regions, notably in the dorsal aspect of the hypothalamic arcuate nucleus (ArcD), which is known to also express NPY ( [25] ), with a few c--fos--positive neurons also found in the lateral aspect of the hypothalamic arcuate nucleus (ArcL). In contrast, PP injection alone induced a marked increase in c--fos immunoreactive neurons in the ArcL (Table 1, Figure 1D and F), which is an area that preferentially expresses POMC, with little induction of c--fos expression in the ArcD. Interestingly, dual administration of PYY3--36 and PP to WT mice led to a significant increase in the number of c--fos positive neurons in both the ArcD and ArcL (Table 1, Figure 1D and G), with the number of c--fos positive neurons being approximately equal to the sum of c--fos positive neurons induced by either peptide alone in the ArcD and ArcL (Table 1) . However, when the combined treatment was applied to Y2−/− mice, a significant increase in the number of c--fos immunoreactive neurons was only detected in the ArcL, but not in the ArcD (Table 2, Figure 2A and B). This is consistent with the expression pattern seen with PP administration alone indicating the effect of PYY3--36 is abolished in the absence of Y2 receptors, with PP retaining its full capacity with intact Y4 receptor signaling. On the contrary, dual administration of PYY3--36 and PP to Y4−/− mice resulted in a marked increase in c--fos expression in the ArcD, but not in the ArcL (Table 2 , Figure 2C and D). Importantly, Y2Y4−/− animals injected with PYY3--36 and PP displayed no significant neuronal activation in the Arc, with the c--fos expression level being similar to that seen in the saline--injected groups (Table 2, Figure 2E and F). Together, our data indicate that PYY3--36 and PP control food intake most likely by signaling through Y2 and Y4 receptor expressing neurons in the ArcD and the ArcL. However, further study using conditional hypothalamic--specific deletion mouse model will be necessary to confirm this assumption. Based on the expression pattern and the number of c--fos positive neurons after double treatment, one can assume that there is an additive action of PYY3--36 and PP in inducing neuron activity in the Arc via different pathways, rather than via synergistic responses on the same pathways.
In addition to assessment of induction of c--fos immunoreactivity, we also evaluated changes in immunoreactivity for phosphorylated extracellular signal--regulated kinases 1 and 2 (p--ERK1/2), a marker of activation of intracellular signaling cascades affected by G--protein coupled receptors, as further functional evidence that PYY3--36 and/or PP activate intracellular processes within the Arc. As shown in Table 3 in the ArcD of WT mice, compared to minor activation in saline injected controls, p--ERK1/2 was clearly induced at 30 min after PYY3--36 treatment alone, with minimal activation by PP injection alone, the pattern of activation being 3), suggesting that PP, but very little PYY3-36, contributes to the neuronal activation in the ArcL in the combined treatment.
Since the majority of c-fos and p-ERK induction in the Arc in response to PYY3-36 appears to be located in the ArcD area, which is known to have a high density of NPY-expressing neurons, we next aimed to determine the degree of activation of these NPY-ergic neurons by injecting PYY3-36 into a transgenic mouse model expressing GFP under control of the endogenous NPY promoter (NPYGFP). In the Arc, 63% of neurons exhibiting c-fos immunostaining at 30 min after injection also showed immunostaining for NPY ( Figure 2G ). Interestingly, some c-fos positive neurons-indicated by red fluorescence in Figure 3 -were not co-localized with PYY3-36. These findings suggest th by acting on both NPY-containing a
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In the DMH of WT mice, the numb rons after combined PYY3-36 and the sum of that induced by either (Table 1, Figure 5A -D). In either Y to basal c-fos expressing neurons injection still led to a significant in (Table 2 ). However, in the absence Y2Y4 2/2 mice, the number of c-fo treatment was not significantly diffe Y2Y4 2/2 control mice (Table 2) , dem receptors are required for the additiv activate neurons in the DMH. consistent with that indicated by induction of c--fos expression. Interestingly, concomitant treatment with both peptides induced an increase in p--ERK1/2-positive neurons in the ArcD to a level that was comparable with that induced by injection of PYY3--36 alone, with only minor p--ERK1/2 activation seen in the ArcL (Table 3 ), indicating that PYY3--36 in the combination treatment is mainly responsible for the neuronal activation seen in the ArcD. On the other hand, in the ArcL of WT mice, PP induced a significant increase in p--ERK1/2 immunoreactive neurons (Table 3) , whereas PYY3--36 was only able to elicit a low level of activation in p--ERK--positive neurons. Similar to the c--fos expression in the ArcL of WT, dual administration of both PYY3--36 and PP induced a neuronal expression pattern in the ArcL that was comparable to that induced by PP injection alone, again with only a minor activation contributed by PYY3--36 ( Table 3) , suggesting that PP, but very little PYY3--36, contributes to the neuronal activation in the ArcL in the combined treatment.
Since the majority of c--fos and p--ERK induction in the Arc in response to PYY3--36 appears to be located in the ArcD area, which is known to have a high density of NPY--expressing neurons, we next aimed to determine the degree of activation of these NPY--ergic neurons by injecting PYY3--36 into a transgenic mouse model expressing GFP under control of the endogenous NPY promoter (NPYGFP). In the Arc, 63% of neurons exhibiting c--fos immunostaining at 30 min after injection also showed immunostaining for NPY ( Figure 2G ). Interestingly, some c--fos positive neurons-indicated by red fluorescence in Figure 3 -were not co--localized with NPY--expressing neurons-indicated by green fluorescence-in the ArcD, the brain region that we have demonstrated to be activated by PYY3--36. These findings suggest that PYY3--36 controls food intake by acting on both NPY--containing and non--NPY neurons in the Arc.
PYY3--36 and PP activate neurons in other key hypothalamic regions
In addition to the effects on the Arc, we also examined the effects of PYY3--36 and/or PP injection on the expression of c--fos in other key hypothalamic regions that are critical in the regulation of food intake and energy homeostasis, including the paraventricular nucleus (PVN), dorso--medial nucleus of the hypothalamus (DMH), ventro--medial nucleus of the hypothalamus (VMH), including both the dorsomedial (VMHDM) and the ventrolateral divisions (VMHVL), and the lateral hypothalamic area (LHA). I.p. injection of PYY3--36 into WT mice induced a marked increase in c--fos immunoreactivity in the PVN (Table 1, Figure 3A and B). By contrast, PP injection did not induce significant c--fos expression in the PVN (Table 1, Figure 3A and C), whereas injection of both PYY3--36 and PP resulted in a similar c--fos expression pattern to that seen after PYY3--36 injection alone (Table 1, Figure 3A , B, and D). Lack of Y2 receptors, as in Y2−/− or Y2Y4−/− mice, but not lack of Y4 receptors, as in Y4−/− mice, blocked the effect of combined treatment to activate c--fos in the PVN (Table 2, Figure 4A-F) , demonstrating the critical involvement of Y2 receptors in PYY3--36--mediated activation of the PVN.
3), suggesting that PP, but very little PYY3-36, contributes to the neuronal activation in the ArcL in the combined treatment.
Since the majority of c-fos and p-ERK induction in the Arc in response to PYY3-36 appears to be located in the ArcD area, which is known to have a high density of NPY-expressing neurons, we next aimed to determine the degree of activation of these NPY-ergic neurons by injecting PYY3-36 into a transgenic mouse model expressing GFP under control of the endogenous NPY promoter (NPYGFP). In the Arc, 63% of neurons exhibiting c-fos immunostaining at 30 min after injection also showed immunostaining for NPY ( Figure 2G) . Interestingly, some c-fos positive neurons-indicated by red fluorescence in Figure 3 Figure 4A-F) , demonstrating the critical involvement of Y2 receptors in PYY3-36-mediated activation of the PVN.
In the DMH of WT mice, the number of c-fos immunoreactive neurons after combined PYY3-36 and PP administration was close to the sum of that induced by either PYY3-36 or PP injection alone (Table 1 , Figure 5A -D). In either Y2 2/2 or Y4 2/2 mice, compared to basal c-fos expressing neurons in saline-injected mice, double injection still led to a significant increase in c-fos positive neurons (Table 2) . However, in the absence of Y2 and Y4 receptors, as in Y2Y4 2/2 mice, the number of c-fos positive neurons in combined treatment was not significantly different from that of saline-injected Y2Y4 2/2 control mice ( Table 2 ), demonstrating that both Y2 and Y4
receptors are required for the additive effects of PYY3-36 and PP to activate neurons in the DMH.
In the VMH of WT mice, PYY3-36 injection alone had no effect on c-fos immunoreactivity, whereas PP induced a significant increase in the number of c-fos immunoreactive neurons in both the VMHDM and VMHVL ( Table 1 ). The combined administration of PYY3-36 and PP led to a similar increase in the number of c-fos immunoreactive neurons to that induced by PP injection alone (Table 1 ). This effect in the VMHDM was mediated by Y4 but not Y2 receptors, as no increases in c-fos immunoreactivity in response 
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Obesity Figure 5A-D) . In either Y2−/− or Y4−/− mice, compared to basal c--fos expressing neurons in saline--injected mice, double injection still led to a significant increase in c--fos positive neurons (Table  2) . However, in the absence of Y2 and Y4 receptors, as in Y2Y4−/− mice, the number of c--fos positive neurons in combined treatment was not significantly different from that of saline--injected Y2Y4−/− control mice ( Table 2 ), demonstrating that both Y2 and Y4 receptors are required for the additive effects of PYY3--36 and PP to activate neurons in the DMH.
In the VMH of WT mice, PYY3--36 injection alone had no effect on c--fos immunoreactivity, whereas PP induced a significant increase in the number of c--fos immunoreactive neurons in both the VMHDM and VMHVL ( Table 1 ). The combined administration of PYY3--36 and PP led to a similar increase in the number of c--fos immunoreactive neurons to that induced by PP injection alone (Table 1 ). This effect in the VMHDM was mediated by Y4 but not Y2 receptors, as no increases in c--fos immunoreactivity in response to PYY3--36 and PP injection was observed in the VMHDM of Y4−/− or Y2Y4−/− mice, while the response remained in Y2−/− mice (Table 2) . Interestingly, in the VMHVL, it appears that other receptors besides Y2 and Y4 may be involved in the PYY3--36 and PP--mediated induction of c--fos immunoreactivity, because the response remains intact in Y2 or Y4 receptor single knockout mice.
to PYY3-36 and PP injection was observed in the VMHDM of Y4 2/2 or Y2Y4 2/2 mice, while the response remained in Y2 2/2 mice (Table 2) . Interestingly, in the VMHVL, it appears that other receptors besides Y2 and Y4 may be involved in the PYY3-36 and tion, either alone or in combination, significantly increased the levels of c-fos immunoreactivity (Table 1) (Table 2 ).
Discussion
In this study, we demonstrate that the satiety peptides PYY3-36 and PP have additive actions to decrease food intake, and that these additive effects are likely mediated by the distinct neuronal pathways activated by signaling through Y2 and Y4 receptors. Indeed, we found that PYY3-36 and PP activate hypothalamic nuclei that are critical in the regulation of appetite and satiety regulation, as demonstrated by c-fos or p-ERK activation. Moreover, some of these hypothalamic nuclei or their subdivisions were activated either www.obesityjournal.org Obesity | VOLUME 21 | NUMBER 12 | DECEMBER 2013 E675
Furthermore, in the LHA of WT mice, both PYY3--36 and PP injection, either alone or in combination, significantly increased the levels of c--fos immunoreactivity (Table 1 ). This effect is likely to be mediated by Y4 but not Y2 receptors, as it was completely abolished in Y4−/− and Y2Y4−/− but not in Y2−/− mice ( Table 2) .
In this study, we demonstrate that the satiety peptides PYY3--36 and PP have additive actions to decrease food intake, and that these additive effects are likely mediated by the distinct neuronal pathways activated by signaling through Y2 and Y4 receptors. Indeed, we found that PYY3--36 and PP activate hypothalamic nuclei that are critical in the regulation of appetite and satiety regulation, as demonstrated by c--fos or p--ERK activation. Moreover, some of these hypothalamic nuclei or their subdivisions were activated either by PYY3--36 or PP, providing an explanation for the additive anorexigenic effects of these peptides.
by PYY3-36 or PP, providing an explanation for the additive anorexigenic effects of these peptides.
Our observation that the Y2 receptor mediates the anorexigenic and central actions of PYY3-36 but not PP, and that the Y4 receptor mediates these actions of PP but not PYY3-36 is consistent with their high affinities for the Y2 and Y4 receptor, respectively (4, 21) .
Comprehensive analysis of mRNA expression of these Y-receptors in the rat has shown that they are abundantly expressed in neurons of the hypothalamus, with particularly high density in the Arc (26) . However, in the mouse brain, as shown here, it appears that there is a clear distinction in expression pattern between the Y2 and Y4 receptors within the Arc, with the former being more highly concentrated in the ArcD and the latter being more abundantly expressed in the ArcL. This species difference in Y-receptor location
The slight difference in expression of Y2 and Y4 receptors within the Arc also coincides with the distribution of different neuronal populations in this area, with-for example-neurons expressing NPY and agouti related peptide (AgRP) being more prevalent in the ArcD, whereas neurons expressing POMC and cocaine amphetamine-related transcript (CART) are more common in the ArcL (25) . Furthermore, within the Arc it has been shown that a large proportion of Y2 receptors are co-localized with NPY neurons, and that Y2 receptors within the Arc likely act as auto-receptors on NPY-ergic neurons to inhibit the synthesis and release of NPY (3, 28, 29) . Consistent with this overlap of Y2 expression with NPY/ AgRP neurons in the ArcD and their role as auto-receptors, we have recently shown that lack of Y2 receptors causes an increase in NPY mRNA and protein expression (29) . Importantly, our current findings also demonstrate that some but not all of the ArcD neurons 
Shi et al.: Additive Effect of PYY3--36 and PP on Feeding
Obesity, 21 (12): E669--78, 2013 Our observation that the Y2 receptor mediates the anorexigenic and central actions of PYY3--36 but not PP, and that the Y4 receptor mediates these actions of PP but not PYY3--36 is consistent with their high affinities for the Y2 and Y4 receptor, respectively ( [4, 21] ). Comprehensive analysis of mRNA expression of these Y--receptors in the rat has shown that they are abundantly expressed in neurons of the hypothalamus, with particularly high density in the Arc ( [26] ). However, in the mouse brain, as shown here, it appears that there is a clear distinction in expression pattern between the Y2 and Y4 receptors within the Arc, with the former being more highly concentrated in the ArcD and the latter being more abundantly expressed in the ArcL. This species difference in Y--receptor location between rat and mouse is not too surprising considering that the rat genome is missing the Y6 receptor, a fully functional receptor in the mouse ( [27] ).
The slight difference in expression of Y2 and Y4 receptors within the Arc also coincides with the distribution of different neuronal populations in this area, with-for example-neurons expressing NPY and agouti related peptide (AgRP) being more prevalent in the ArcD, whereas neurons expressing POMC and cocaine amphetamine--related transcript (CART) are more common in the ArcL ( [25] ). Furthermore, within the Arc it has been shown that a large proportion of Y2 receptors are co--localized with NPY neurons, and that Y2 receptors within the Arc likely act as auto--receptors on NPY--ergic neurons to inhibit the synthesis and release of NPY neurons in the ArcD, and also raising the possibility that PYY3-36 may bind to Y2 receptors located on non-NPY-ergic neurons in the ArcD to subsequently reduce appetite via other pathways.
Importantly, this work also shows that Y2 receptors and Y4 receptors are not only critical for PYY3-36-or PP-induced c-fos activation in the Arc but also in other hypothalamic nuclei, including the PVN, DMH, VMH, and LHA. Since the Arc innervates virtually the entire hypothalamus (30) , and since these second-order neurons are not readily accessible to blood-borne PYY3-36 or PP, it is likely that PYY3-36 and PP predominantly act on Y2 or Y4 receptors in the Arc and this in turn leads to activation of distinct subsets of downstream neurons located in these key hypothalamic nuclei that regulate appetite.
Of note there was a previous study by Neary et al. also investigating the effects of double treatment with PP and PYY3-36 on food intake, which did not find a significant additive effect on food intake (31); however the mechanism behind that was not explored. Importantly, there are a few differences in the design and analysis between the previous and our study.
Firstly, the mice used had a different genetic background (C57BL/6 versus C57/B16-129SvJ in our study). Secondly, the dose of the peptides was different with a considerable lower dose used by Neary et al. Thirdly, and probably most critical, it is not clear from the methods whether spillage has been taken into account when calculating actual food consumed. Therefore, these differences between the two studies make direct comparisons difficult.
In summary, we demonstrate that combined PYY3-36 and PP injection decreases food intake in an additive manner. Our finding also highlights the fact that multiple pathways have arisen during evolution to control this important physiological process of controlling . Importantly, our current findings also demonstrate that some but not all of the ArcD neurons activated by i.p. PYY3--36 are co--localized with NPY, suggesting that PYY3--36--induced control of food intake is, at least in part, mediated by direct action on Y2 auto--receptors on NPY--ergic neurons in the ArcD, and also raising the possibility that PYY3--36 may bind to Y2 receptors located on non--NPY--ergic neurons in the ArcD to subsequently reduce appetite via other pathways.
Importantly, this work also shows that Y2 receptors and Y4 receptors are not only critical for PYY3--36--or PP--induced c--fos activation in the Arc but also in other hypothalamic nuclei, including the PVN, DMH, VMH, and LHA. Since the Arc innervates virtually the entire hypothalamus ( [30] ), and since these second--order neurons are not readily accessible to blood--borne PYY3--36 or PP, it is likely that PYY3--36 and PP predominantly act on Y2 or Y4 receptors in the Arc and this in turn leads to activation of distinct subsets of downstream neurons located in these key hypothalamic nuclei that regulate appetite.
Of note there was a previous study by Neary et al. also investigating the effects of double treatment with PP and PYY3--36 on food intake, which did not find a significant additive effect on food intake ( [31] ); however the mechanism behind that was not explored. Importantly, there are a few differences in the design and analysis between the previous and our study. Firstly, the mice used had a different genetic background (C57BL/6 versus C57/B16-129SvJ in our study). Secondly, the dose of the peptides was different with a considerable lower dose used by Neary et al. Thirdly, and probably most critical, it is not clear from the methods whether spillage has been taken into account when calculating actual food consumed. Therefore, these differences between the two studies make direct comparisons difficult.
In summary, we demonstrate that combined PYY3--36 and PP injection decreases food intake in an additive manner. Our finding also highlights the fact that multiple pathways have arisen during evolution to control this important physiological process of controlling appetite to guarantee effective supply of nutrition to the organism. Although the long--term efficacy for appetite control and weight reduction and the potential side effects of combination treatment is yet to be determined, this prominent additive effect on inhibiting food intake highlights the potential therapeutic value of a combination approach that targets multiple Y receptors and/or multiple neuronal pathways to decrease food intake and subsequently reduce body weight. References
